Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
- PMID: 19070661
- DOI: 10.1016/j.ejpb.2008.11.010
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
Abstract
For over half a century extensive research has been undertaken for the control of cancer. However, success has been limited to certain malignancies, and surgical intervention is potentially curative for early stage patients. For the majority of patients with advanced stage of cancer, the treatment is limited to chemotherapy or radiation. Chemotherapy in particular has limitations due to the lack of selectivity with severe toxicity. Under these circumstances tumor-targeted delivery of anticancer drugs is perhaps one of the most important steps for cancer chemotherapy. We reported such a drug for the first time, styrene-maleic acid copolymer-conjugated neocarzinostatin (SMANCS) in 1979, and it eventually led to formulate the concept of the enhanced permeability and retention (EPR) effect of solid tumors in 1986. Monoclonal antibody conjugates are another direction, of which interest is increasing recently though with limited success. The EPR-effect appears as a universal phenomenon in solid tumors which warrants the development of other polymeric drugs or nanomedicine. EPR-effect is applicable for any biocompatible macromolecular compounds above 40 kDa, even larger than 800 kDa, or of the size of bacteria; thus complexed molecules like micelles and liposomes containing anticancer drugs are hallmark examples. The drug concentration in tumor compared to that of the blood (T/B ratio) can be usually as high as 10-30 times. In case of SMANCS/Lipiodol given via tumor feeding artery, the T/B ratio can be as high as 2000, a real pin-point targeting. EPR-effect is not just passive targeting for momentary tumor delivery, but it means prolonged drug retention for more than several weeks or longer. This review describes the pathophysiological mechanisms of the EPR-effect, architectural difference of tumor blood vessel, various factors involved and artificial augmentation of EPR-effect with respect to tumor-selective delivery, and then advantages and problems of macromolecular drugs.
Similar articles
-
Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.Methods Mol Biol. 2010;624:25-37. doi: 10.1007/978-1-60761-609-2_3. Methods Mol Biol. 2010. PMID: 20217587
-
Passive and active drug targeting: drug delivery to tumors as an example.Handb Exp Pharmacol. 2010;(197):3-53. doi: 10.1007/978-3-642-00477-3_1. Handb Exp Pharmacol. 2010. PMID: 20217525 Review.
-
Advances in polymeric micelles for drug delivery and tumor targeting.Nanomedicine. 2010 Dec;6(6):714-29. doi: 10.1016/j.nano.2010.05.005. Epub 2010 Jun 11. Nanomedicine. 2010. PMID: 20542144 Review.
-
Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects.Adv Drug Deliv Rev. 2011 Mar 18;63(3):161-9. doi: 10.1016/j.addr.2010.09.003. Epub 2010 Oct 28. Adv Drug Deliv Rev. 2011. PMID: 20869415 Review.
-
Passive tumor targeting of soluble macromolecules and drug conjugates.Crit Rev Ther Drug Carrier Syst. 1992;9(2):135-87. Crit Rev Ther Drug Carrier Syst. 1992. PMID: 1386002 Review.
Cited by
-
What is the Reason That the Pharmacological Future of Chemotherapeutics in the Treatment of Lung Cancer Could Be Most Closely Related to Nanostructures? Platinum Drugs in Therapy of Non-Small and Small Cell Lung Cancer and Their Unexpected, Possible Interactions. The Review.Int J Nanomedicine. 2024 Sep 14;19:9503-9547. doi: 10.2147/IJN.S469217. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39296940 Free PMC article. Review.
-
The elasticity of silicone-stabilized liposomes has no impact on their in vivo behavior.J Nanobiotechnology. 2024 Aug 5;22(1):467. doi: 10.1186/s12951-024-02698-9. J Nanobiotechnology. 2024. PMID: 39103899 Free PMC article.
-
Metal-based nanoparticle in cancer treatment: lessons learned and challenges.Front Bioeng Biotechnol. 2024 Jul 11;12:1436297. doi: 10.3389/fbioe.2024.1436297. eCollection 2024. Front Bioeng Biotechnol. 2024. PMID: 39055339 Free PMC article. Review.
-
Cisplatin-based Liposomal Nanocarriers for Drug Delivery in Lung Cancer Therapy: Recent Progress and Future Outlooks.Curr Pharm Des. 2024;30(36):2850-2881. doi: 10.2174/0113816128304923240704113319. Curr Pharm Des. 2024. PMID: 39051580 Review.
-
Sustained delivery of celecoxib from nanoparticles embedded in hydrogel injected into the biopsy cavity to prevent biopsy-induced breast cancer metastasis.Breast Cancer Res Treat. 2024 Nov;208(1):165-177. doi: 10.1007/s10549-024-07410-x. Epub 2024 Jul 5. Breast Cancer Res Treat. 2024. PMID: 38969944 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources